Skip to main content
For laboratory research use only. Not for human or veterinary use.
Free UPS Ground on 3+ vials · same business day by 2 PM ET
Bench Grade Peptides

Thymosin Alpha-1 5mg

28-residue acetylated thymic peptide studied in immune-modulation research.

Thymosin Alpha-1 5mg is supplied by Bench Grade Peptides as a lyophilized powder in a sealed, lot-numbered vial, for laboratory research use only — not for human or veterinary use.

Its published Certificate of Analysis (lot 00011/0011, analyzed September 20, 2026) is from AV Analytics, a third-party laboratory, and reports 99.79% purity by HPLC; every published lot is listed on the product's COA page. Vials ship at ambient temperature in protective packaging from Florida (Bench Grade Peptides LLC is registered in Dover, Delaware), with storage notes on the lot's certificate.

28-residue acetylated thymic peptide studied in immune-modulation research.

The primary literature on this compound includes Goldstein et al., Ann NY Acad Sci (2007). The references below link directly to the published record.

Lots are synthesized in the USA and verified by HPLC; where a lot's Certificate of Analysis is published, it is in the COA library. It is supplied strictly for laboratory research use.

Research use only. Everything on this page describes laboratory research. This compound is supplied strictly for in-vitro research use; it has not been evaluated or approved by the FDA and is not for human or veterinary use, and nothing here is a protocol or a recommendation.

Published research

  • The efficacy and safety of thymosin alpha-1 for sepsis (TESTS): multicentre, double blinded, randomised, placebo controlled, phase 3 trial
    Liu D, et al. BMJ. 2025.PubMed →
  • Safety and efficacy of Thymosin alpha-1 in the treatment of hepatitis B virus-related acute-on-chronic liver failure: a randomized controlled trial
    Shen Y, et al. Hepatol Int. 2022.PubMed →
  • The efficacy of thymosin alpha 1 for severe sepsis (ETASS): a multicenter, single-blind, randomized and controlled trial
    Wu J, et al. Crit Care. 2013.PubMed →
  • Thymosin alpha 1 is associated with improved cellular immunity and reduced infection rate in severe acute pancreatitis patients in a double-blind randomized control study
    Wang X, et al. Inflammation. 2011.PubMed →
  • The efficacy and safety of thymosin alpha-1 in Japanese patients with chronic hepatitis B; results from a randomized clinical trial
    Iino S, et al. J Viral Hepat. 2005.PubMed →
  • Efficacy of thymosin alpha1 in patients with chronic hepatitis B: a randomized, controlled trial
    Andreone P, et al. Liver. 1996.PubMed →

Further reading in the lab library

Browse the catalog